NASDAQ:VCYT Veracyte (VCYT) Stock Price, News & Analysis $40.08 -0.06 (-0.15%) As of 12:56 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Veracyte Stock (NASDAQ:VCYT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Veracyte alerts:Sign Up Key Stats Today's Range$39.50▼$41.4550-Day Range$40.14▼$59.7852-Week Range$29.45▼$60.91Volume322,522 shsAverage Volume1.10 million shsMarket Capitalization$3.22 billionP/E Ratio28.41Dividend YieldN/APrice Target$55.78Consensus RatingModerate Buy Company Overview Veracyte, Inc. is a diagnostics company that develops and commercializes genomic tests designed to help physicians diagnose cancer, assess disease risk and guide treatment decisions. The company combines genomic data with bioinformatics and machine-learning technologies to provide clinically actionable information from patient tissue samples. Veracyte’s portfolio includes Afirma tests for evaluating thyroid nodules, Decipher tests for assessing the risk and biological characteristics of prostate cancer, and Prosigna for classifying and evaluating recurrence risk in certain breast cancers. Its offerings also include diagnostic tools for lung cancer, including tests intended to help evaluate indeterminate lung nodules and improve treatment planning. The company’s tests are generally used by physicians, hospitals and laboratories as part of routine clinical decision-making. Founded in 2008, Veracyte is headquartered in South San Francisco, California. It provides testing services through its laboratories and commercial partnerships, primarily serving the United States while also supporting international markets. Marc Stapley serves as the company’s chief executive officer.AI Generated. May Contain Errors. Read More Veracyte Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks84th Percentile Overall ScoreVCYT MarketRank™: Veracyte scored higher than 84% of companies evaluated by MarketBeat, and ranked 90th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingVeracyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 2 strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialVeracyte has a consensus price target of $55.78, representing about 39.7% upside from its current price of $39.92.Amount of Analyst CoverageVeracyte has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Veracyte's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth16.67% Earnings GrowthEarnings for Veracyte are expected to grow by 16.67% in the coming year, from $1.32 to $1.54 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Veracyte is 28.34, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.93.Price to Earnings Ratio vs. SectorThe P/E ratio of Veracyte is 28.34, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.78.Price to Book Value per Share RatioVeracyte has a P/B Ratio of 2.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Veracyte's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.21% of the float of Veracyte has been sold short.Short Interest Ratio / Days to CoverVeracyte has a short interest ratio ("days to cover") of 5.84.Change versus previous monthShort interest in Veracyte has recently increased by 18.96%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVeracyte does not currently pay a dividend.Dividend GrowthVeracyte does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.15 News SentimentVeracyte has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Veracyte this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for VCYT on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows4 people have added Veracyte to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Veracyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,139,324.00 in company stock.Percentage Held by Insiders1.60% of the stock of Veracyte is held by insiders.Percentage Held by InstitutionsVeracyte has minimal institutional ownership at this time.Read more about Veracyte's insider trading history. Receive VCYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VCYT Stock News HeadlinesShattuck Labs (NASDAQ:STTK) & Veracyte (NASDAQ:VCYT) Financial ComparisonSeptember 16 at 4:16 AM | americanbankingnews.comVeracyte, Inc. (NASDAQ:VCYT) Given Average Rating of "Moderate Buy" by AnalystsSeptember 16 at 2:15 AM | americanbankingnews.comMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by robots but by America's oil and gas infrastructure. It's called the Patriot Income Plan, or P.I.P., and it pays 10% a year across 42 separate distribution dates. This year it's on track to pay out a record 53 billion dollars. Think of it as a personal stake in the world's largest energy producer, structured to deliver income on a regular schedule.September 16 at 1:00 AM | Freedom Financial (Ad)Veracyte Adds Another Stream to Bladder Franchise, UBS SaysSeptember 15 at 12:49 PM | marketscreener.comMVeracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 15 at 10:31 AM | seekingalpha.comVeracyte, Inc.: Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing PlatformSeptember 15 at 7:48 AM | finanznachrichten.deInsider Selling: Veracyte (NASDAQ:VCYT) EVP Sells 3,254 SharesSeptember 5, 2026 | insidertrades.comMuna Bhanji Sells 1,864 Shares of Veracyte (NASDAQ:VCYT) StockSeptember 4, 2026 | insidertrades.comSee More Headlines VCYT Stock Analysis - Frequently Asked Questions How have VCYT shares performed this year? Veracyte's stock was trading at $42.10 at the beginning of 2026. Since then, VCYT stock has decreased by 5.2% and is now trading at $39.9220. How were Veracyte's earnings last quarter? Veracyte, Inc. (NASDAQ:VCYT) released its earnings results on Thursday, July, 30th. The biotechnology company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.13. The company's quarterly revenue was up 15.5% on a year-over-year basis. Read the conference call transcript. Does Veracyte have any subsidiaries? Veracyte subsidiaries include these companies: HalioDx Inc., Decipher Biosciences Inc., Allegro Diagnostics, Decipher Corp., Delight Merger Sub II LLC, Veracyte Global B.V., Veracyte International Corp., and Veracyte SAS. When did Veracyte IPO? Veracyte (VCYT) raised $70 million in an initial public offering (IPO) on Wednesday, October 30th 2013. The company issued 5,000,000 shares at $13.00-$15.00 per share. Who are Veracyte's major shareholders? Veracyte's top institutional investors include BlackRock Inc. (16.78%), Wellington Management Group LLP (2.83%), William Blair Investment Management LLC (1.78%) and Bank of America Corp DE (1.37%). Insiders that own company stock include Marc Stapley, Rebecca Chambers, Phillip G Febbo, John Leite, Annie Mcguire, Robert S Epstein, Jonathan Wygant, Jonathan Wygant, Muna Bhanji, Evan/ Fa Jones, Jens Holstein and Karin Eastham. View institutional ownership trends. How do I buy shares of Veracyte? Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Veracyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that Veracyte investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings7/30/2026Today9/16/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 VCYT's financial health is in the Yellow zone, according to TradeSmith. VCYT has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:VCYT CIK1384101 Webwww.veracyte.com Phone(650) 243-6300Fax650-243-6301Employees755Year Founded2008Price Target and Rating Average Price Target for Veracyte$55.78 High Price Target$69.00 Low Price Target$44.00 Potential Upside/Downside+39.7%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)$1.41 Trailing P/E Ratio28.34 Forward P/E Ratio30.24 P/E GrowthN/ANet Income$66.35 million Net Margins20.37% Pretax Margin20.65% Return on Equity9.26% Return on Assets8.61% Debt Debt-to-Equity RatioN/A Current Ratio9.16 Quick Ratio8.80 Sales & Book Value Annual Sales$517.15 million Price / Sales6.21 Cash Flow$1.44 per share Price / Cash Flow27.67 Book Value$16.57 per share Price / Book2.41Miscellaneous Outstanding Shares80,390,000Free Float79,105,000Market Cap$3.21 billion OptionableOptionable Beta1.93 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:VCYT) was last updated on 9/16/2026 by MarketBeat.com Staff. From Our PartnersAmerica Relied on Its Biggest Rival for This Military MetalAntimony strengthens ammunition, missiles, sensors, batteries and semiconductors, yet the US ceded most produc...i2i Marketing Group, LLC | Sponsored$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredThe national debt just passed $39 trillionThe U.S. national debt just topped $39 trillion, up nearly $3 trillion in a single year and on pace to hit $40...US Gold Bureau | SponsoredThis Gold Explorer Is Approaching Its Biggest Milestone YetA little-known Arizona gold explorer just hit 66.2 metres grading 6.57 g/t gold, including 20.7 metres at 18.2...Wall Street Logic | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredGold just passed our debt as the world's #1 assetChina's US Treasury holdings have fallen from a peak of $1.32 trillion to roughly $659 billion, an 18-year low...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veracyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Veracyte With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
